| Year |
Citation |
Score |
| 2022 |
Dusetzina SB, Sarpatwari A, Carrier MA, Hansen RA, Keating NL, Huskamp HA. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D. Jama Internal Medicine. 181: 1605-1611. PMID 34661600 DOI: 10.1001/jamainternmed.2021.5997 |
0.458 |
|
| 2020 |
Yeung K, Barthold D, Dusetzina SB, Basu A. Patient and Plan Spending after State Specialty-Drug Out-of-Pocket Spending Caps. The New England Journal of Medicine. 383: 558-566. PMID 32757524 DOI: 10.1056/Nejmsa1910366 |
0.335 |
|
| 2019 |
Dusetzina SB, Oberlander J. Advancing Legislation on Drug Pricing - Is There a Path Forward? The New England Journal of Medicine. 381: 2081-2084. PMID 31774951 DOI: 10.1056/Nejmp1914044 |
0.316 |
|
| 2019 |
Mitchell AP, Kinlaw AC, Peacock-Hinton S, Dusetzina SB, Sanoff HK, Lund JL. Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. The Oncologist. PMID 31611329 DOI: 10.1634/Theoncologist.2019-0338 |
0.33 |
|
| 2019 |
Dusetzina SB, Keating NL, Huskamp HA. Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices. The New England Journal of Medicine. PMID 31483987 DOI: 10.1056/Nejmp1908688 |
0.314 |
|
| 2018 |
Dusetzina SB, Mello MM. Disclosing Prescription-Drug Prices in Advertisements - Legal and Public Health Issues. The New England Journal of Medicine. 379: 2290-2293. PMID 30428275 DOI: 10.1056/Nejmp1814065 |
0.311 |
|
| 2018 |
Knight TG, Deal AM, Dusetzina SB, Muss HB, Choi SK, Bensen JT, Williams GR. Financial Toxicity in Adults With Cancer: Adverse Outcomes and Noncompliance. Journal of Oncology Practice. JOP1800120. PMID 30355027 DOI: 10.1200/Jop.18.00120 |
0.344 |
|
| 2018 |
Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018778894. PMID 30113885 DOI: 10.1200/Jco.2018.77.8894 |
0.361 |
|
| 2018 |
Rotenstein LS, Dusetzina SB, Keating NL. Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit. Journal of Managed Care & Specialty Pharmacy. 24: 494-502. PMID 29799324 DOI: 10.18553/Jmcp.2018.24.6.494 |
0.304 |
|
| 2018 |
Smitherman AB, Mohabir D, Wilkins TM, Blatt J, Nichols HB, Dusetzina SB. Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors. The Journal of Pediatrics. PMID 29395178 DOI: 10.1016/J.Jpeds.2017.11.063 |
0.302 |
|
| 2018 |
Pinheiro LC, Check D, Rosenstein D, Reeder-Hayes KE, Dusetzina S. Investigating Hispanic disparities in supportive medication use among Medicare beneficiaries with breast cancer. Journal of Clinical Oncology. 36: 154-154. DOI: 10.1200/Jco.2018.36.7_Suppl.154 |
0.346 |
|
| 2017 |
Dusetzina SB, Huskamp HA, Winn AN, Basch E, Keating NL. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. Jama Oncology. PMID 29121177 DOI: 10.1001/Jamaoncol.2017.3598 |
0.344 |
|
| 2017 |
Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017737437. PMID 29023215 DOI: 10.1200/Jco.2017.73.7437 |
0.335 |
|
| 2017 |
Falchook AD, Dusetzina SB, Tian F, Basak R, Selvam N, Chen RC. Aggressive End-of-Life Care for Metastatic Cancer Patients Younger Than Age 65 Years. Journal of the National Cancer Institute. 109. PMID 28954284 DOI: 10.1093/Jnci/Djx028 |
0.313 |
|
| 2017 |
Reeder-Hayes KE, Meyer AM, Hinton SP, Meng K, Carey LA, Dusetzina SB. Comparative Toxicity and Effectiveness of Trastuzumab-Based Chemotherapy Regimens in Older Women With Early-Stage Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016714345. PMID 28727517 DOI: 10.1200/Jco.2016.71.4345 |
0.362 |
|
| 2017 |
Dusetzina SB, Conti RM, Yu NL, Bach PB. Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. Jama Internal Medicine. PMID 28558108 DOI: 10.1001/Jamainternmed.2017.1885 |
0.342 |
|
| 2017 |
Olszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017722447. PMID 28541791 DOI: 10.1200/Jco.2017.72.2447 |
0.368 |
|
| 2017 |
Chou YT, Winn AN, Rosenstein DL, Dusetzina SB. Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiology and Drug Safety. PMID 28317314 DOI: 10.1002/Pds.4198 |
0.322 |
|
| 2017 |
Mahendraratnam N, Dusetzina SB, Farley JF. Prescription Drug Utilization and Reimbursement Increased Following State Medicaid Expansion in 2014. Journal of Managed Care & Specialty Pharmacy. 23: 355-363. PMID 28230452 DOI: 10.18553/Jmcp.2017.23.3.355 |
0.353 |
|
| 2017 |
Smitherman AB, Mohabir D, Wilkins T, Blatt J, Nichols H, Dusetzina S. Early post-therapy prescription drug usage among survivors of childhood cancers. Journal of Clinical Oncology. 35: 147-147. DOI: 10.1200/Jco.2017.35.5_Suppl.147 |
0.351 |
|
| 2017 |
Rotenstein L, Dusetzina S, Keating NL. Relationship between out-of-pocket spending and drug value for oral oncolytics reimbursed by commercial insurers: 2007-2014. Journal of Clinical Oncology. 35: 6524-6524. DOI: 10.1200/Jco.2017.35.15_Suppl.6524 |
0.359 |
|
| 2017 |
Olszewski AJ, Dusetzina S, Davidoff AJ, Trivedi AN. Closure of Medicare Part D coverage gap by the Affordable Care Act (ACA) and use of oral anti-myeloma agents. Journal of Clinical Oncology. 35: 6522-6522. DOI: 10.1200/Jco.2017.35.15_Suppl.6522 |
0.347 |
|
| 2017 |
Mitchell AP, Winn A, Dusetzina S. Pharmaceutical industry payments and oncologist drug selection. Journal of Clinical Oncology. 35: 6510-6510. DOI: 10.1200/Jco.2017.35.15_Suppl.6510 |
0.354 |
|
| 2016 |
Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, Dusetzina S. Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among breast cancer patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 292. PMID 28152883 DOI: 10.1200/Jco.2016.34.7_Suppl.292 |
0.355 |
|
| 2016 |
Winn AN, Keating NL, Dusetzina SB. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4323-4328. PMID 27998234 DOI: 10.1200/Jco.2016.67.4184 |
0.312 |
|
| 2016 |
Pace LE, Dusetzina SB, Keating NL. Early Impact Of The Affordable Care Act On Oral Contraceptive Cost Sharing, Discontinuation, And Nonadherence. Health Affairs (Project Hope). 35: 1616-24. PMID 27605641 DOI: 10.1377/Hlthaff.2015.1624 |
0.317 |
|
| 2016 |
Check DK, Reeder-Hayes KE, Zullig LL, Weinberger M, Basch EM, Dusetzina SB. Examining racial variation in antiemetic use and post-chemotherapy health care utilization for nausea and vomiting among breast cancer patients. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 27465051 DOI: 10.1007/S00520-016-3338-4 |
0.338 |
|
| 2016 |
Dusetzina SB. Share Of Specialty Drugs In Commercial Plans Nearly Quadrupled, 2003-14. Health Affairs (Project Hope). 35: 1241-1246. PMID 27385240 DOI: 10.1377/Hlthaff.2015.1657 |
0.306 |
|
| 2016 |
Pace LE, Dusetzina SB, Keating NL. Early Impact of the Affordable Care Act on Uptake of Long-acting Reversible Contraceptive Methods. Medical Care. PMID 27213549 DOI: 10.1097/Mlr.0000000000000551 |
0.305 |
|
| 2016 |
Check DK, Samuel CA, Rosenstein DL, Dusetzina SB. Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27161968 DOI: 10.1200/Jco.2015.64.8162 |
0.315 |
|
| 2016 |
Winn AN, Dusetzina SB. The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiology and Drug Safety. PMID 27125337 DOI: 10.1002/Pds.4012 |
0.315 |
|
| 2016 |
Dusetzina SB. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014. Jama Oncology. PMID 27123993 DOI: 10.1001/Jamaoncol.2016.0648 |
0.333 |
|
| 2016 |
Check DK, Rosenstein DL, Dusetzina SB. Early supportive medication use and end-of-life care among Medicare beneficiaries with advanced breast cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 26994634 DOI: 10.1007/S00520-016-3174-6 |
0.327 |
|
| 2016 |
Check DK, Reeder-Hayes KE, Basch EM, Zullig LL, Weinberger M, Dusetzina SB. Investigating racial disparities in use of NK1 receptor antagonists to prevent chemotherapy-induced nausea and vomiting among women with breast cancer. Breast Cancer Research and Treatment. PMID 26968396 DOI: 10.1007/S10549-016-3747-6 |
0.332 |
|
| 2016 |
Ellis SD, Chen RC, Dusetzina SB, Wheeler SB, Jackson GL, Nielsen ME, Carpenter WR, Weinberger M, Ellis SD, Chen RC, Dusetzina SB, Wheeler SB, Jackson GL, Nielsen ME, Carpenter WR, et al. ReCAP: Are Small Reimbursement Changes Enough to Change Cancer Care? Reimbursement Variation in Prostate Cancer Treatment. Journal of Oncology Practice / American Society of Clinical Oncology. PMID 26957641 DOI: 10.1200/Jop.2015.007344 |
0.307 |
|
| 2016 |
Dusetzina SB, Keating NL. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 375-80. PMID 26644524 DOI: 10.1200/Jco.2015.63.7736 |
0.366 |
|
| 2016 |
Chen RC, Falchook AD, Tian F, Basak R, Hanson L, Selvam N, Dusetzina S. Aggressive care at the end-of-life for younger patients with cancer: Impact of ASCO's Choosing Wisely campaign. Journal of Clinical Oncology. 34: LBA10033-LBA10033. DOI: 10.1200/Jco.2016.34.18_Suppl.Lba10033 |
0.33 |
|
| 2016 |
Mahendraratnam N, Dusetzina S, Farley J. Early Impact Of Medicaid Expansion On Prescription Drug Utilization And Spending Value in Health. 19: A7-A8. DOI: 10.1016/J.Jval.2016.03.055 |
0.311 |
|
| 2015 |
Roberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing. Breast Cancer Research and Treatment. 153: 191-200. PMID 26216535 DOI: 10.1007/S10549-015-3518-9 |
0.308 |
|
| 2015 |
Roberts MC, Dusetzina SB. Use and Costs for Tumor Gene Expression Profiling Panels in the Management of Breast Cancer From 2006 to 2012: Implications for Genomic Test Adoption Among Private Payers. Journal of Oncology Practice / American Society of Clinical Oncology. 11: 273-7. PMID 26105668 DOI: 10.1200/Jop.2015.003624 |
0.313 |
|
| 2015 |
Dusetzina SB, Ellis S, Freedman RA, Conti RM, Winn AN, Chambers JD, Alexander GC, Huskamp HA, Keating NL. How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. Journal of Oncology Practice / American Society of Clinical Oncology. 11: 313-8. PMID 26060224 DOI: 10.1200/Jop.2015.004218 |
0.325 |
|
| 2015 |
Dusetzina SB, Basch E, Keating NL. For uninsured cancer patients, outpatient charges can be costly, putting treatments out of reach. Health Affairs (Project Hope). 34: 584-91. PMID 25847640 DOI: 10.1377/Hlthaff.2014.0801 |
0.315 |
|
| 2015 |
Roberts MC, Wheeler SB, Reeder-Hayes K, Dusetzina SB, Dinan M, Weinberger M. Abstract B53: Racial variation in the uptake of a 21-tumor gene assay in the Carolina Breast Cancer Study cohort Cancer Epidemiology, Biomarkers & Prevention. 24. DOI: 10.1158/1538-7755.Disp14-B53 |
0.322 |
|
| 2014 |
Stevenson DG, O'Malley AJ, Dusetzina SB, Mitchell SL, Zarowitz BJ, Chernew ME, Newhouse JP, Huskamp HA. Effect of Part D coverage restrictions for antidepressants, antipsychotics, and cholinesterase inhibitors on related nursing home resident outcomes. Journal of the American Geriatrics Society. 62: 1666-74. PMID 25123044 DOI: 10.1111/Jgs.12988 |
0.322 |
|
| 2014 |
Dusetzina SB, Muluneh B, Khan T, Richards KL, Keating NL. Obstacles to affordable cancer treatments. North Carolina Medical Journal. 75: 257-60. PMID 25046090 DOI: 10.18043/Ncm.75.4.257 |
0.339 |
|
| 2014 |
Reeder-Hayes KE, Ellis SD, Dusetzina S, Wheeler SB. Cost-effectiveness of alternative adjuvant bisphosphonate regimens in postmenopausal women with early breast cancer. Journal of Clinical Oncology. 32: 6565-6565. DOI: 10.1200/Jco.2014.32.15_Suppl.6565 |
0.349 |
|
| 2013 |
Pace LE, Dusetzina SB, Fendrick AM, Keating NL, Dalton VK. The impact of out-of-pocket costs on the use of intrauterine contraception among women with employer-sponsored insurance. Medical Care. 51: 959-63. PMID 24036995 DOI: 10.1097/Mlr.0B013E3182A97B5D |
0.321 |
|
| 2013 |
Huskamp HA, Stevenson DG, O'Malley AJ, Dusetzina SB, Mitchell SL, Zarowitz BJ, Chernew ME, Newhouse JP. Medicare Part D plan generosity and medication use among dual-eligible nursing home residents. Medical Care. 51: 894-900. PMID 24025658 DOI: 10.1097/Mlr.0B013E31829Fafdc |
0.308 |
|
| 2013 |
Dusetzina SB, Mack CD, Stürmer T. Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics. Plos One. 8: e63973. PMID 23667693 DOI: 10.1371/Journal.Pone.0063973 |
0.321 |
|
| 2013 |
Conti RM, Dusetzina SB, Herbert AC, Berndt ER, Huskamp HA, Keating NL. The impact of emerging safety and effectiveness evidence on the use of physician-administered drugs: the case of bevacizumab for breast cancer. Medical Care. 51: 622-7. PMID 23604014 DOI: 10.1097/Mlr.0B013E318290216F |
0.343 |
|
| 2013 |
Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Confounding control in a nonexperimental study of STAR*D data: logistic regression balanced covariates better than boosted CART. Annals of Epidemiology. 23: 204-9. PMID 23419508 DOI: 10.1016/J.Annepidem.2013.01.004 |
0.503 |
|
| 2013 |
Ellis AR, Dusetzina SB, Hansen RA, Gaynes BN, Farley JF, Stürmer T. Investigating differences in treatment effect estimates between propensity score matching and weighting: a demonstration using STAR*D trial data. Pharmacoepidemiology and Drug Safety. 22: 138-44. PMID 23280682 DOI: 10.1002/Pds.3396 |
0.478 |
|
| 2013 |
Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL. Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Research and Treatment. 137: 285-96. PMID 23149465 DOI: 10.1007/S10549-012-2330-Z |
0.331 |
|
| 2013 |
Reeder-Hayes KE, Meyer A, Dusetzina S, Liu H, Wheeler SB. Racial disparities in initiation of endocrine therapy for early-stage breast cancer. Journal of Clinical Oncology. 31: 6572-6572. DOI: 10.1200/Jco.2013.31.15_Suppl.6572 |
0.301 |
|
| 2012 |
Dusetzina SB, Weinberger M, Gaynes BN, Farley JF, Sleath B, Hansen RA. Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents. Pharmacotherapy. 32: 1085-94. PMID 23208835 DOI: 10.1002/Phar.1148 |
0.511 |
|
| 2012 |
Dusetzina SB, Farley JF, Weinberger M, Gaynes BN, Sleath B, Hansen RA. Treatment use and costs among privately insured youths with diagnoses of bipolar disorder. Psychiatric Services (Washington, D.C.). 63: 1019-25. PMID 22855210 DOI: 10.1176/Appi.Ps.201100516 |
0.494 |
|
| 2012 |
Dusetzina SB, Busch AB, Conti RM, Donohue JM, Alexander GC, Huskamp HA. Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiology and Drug Safety. 21: 1251-60. PMID 22553074 DOI: 10.1002/Pds.3272 |
0.309 |
|
| 2012 |
Katz AJ, Dusetzina SB, Farley JF, Ellis AR, Gaynes BN, Castillo WC, Stürmer T, Hansen RA. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant. Pharmacotherapy. 32: 234-43. PMID 22392456 DOI: 10.1002/J.1875-9114.2011.01020.X |
0.523 |
|
| 2012 |
Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC. Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Medical Care. 50: 466-78. PMID 22266704 DOI: 10.1097/Mlr.0B013E318245A160 |
0.322 |
|
| 2012 |
Gaynes BN, Dusetzina SB, Ellis AR, Hansen RA, Farley JF, Miller WC, Stürmer T. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. Journal of Clinical Psychopharmacology. 32: 114-9. PMID 22198447 DOI: 10.1097/Jcp.0B013E31823F705D |
0.523 |
|
| 2012 |
Hansen RA, Dusetzina SB, Ellis AR, Stürmer T, Farley JF, Gaynes BN. Risk of adverse events in treatment-resistant depression: propensity-score-matched comparison of antidepressant augment and switch strategies. General Hospital Psychiatry. 34: 192-200. PMID 22079151 DOI: 10.1016/J.Genhosppsych.2011.10.001 |
0.508 |
|
| 2011 |
Dusetzina SB, Gaynes BN, Weinberger M, Farley JF, Sleath B, Hansen RA. Receipt of guideline-concordant pharmacotherapy among children with new diagnoses of bipolar disorder. Psychiatric Services (Washington, D.C.). 62: 1443-9. PMID 22193791 DOI: 10.1176/Appi.Ps.000452011 |
0.498 |
|
| 2011 |
Gaynes BN, Farley JF, Dusetzina SB, Ellis AR, Hansen RA, Miller WC, Stürmer T. Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression? Depression and Anxiety. 28: 989-98. PMID 21898717 DOI: 10.1002/Da.20898 |
0.505 |
|
| 2011 |
Dusetzina SB, Caleb Alexander G. Drug vs class-specific black box warnings: does one bad drug spoil the bunch? Journal of General Internal Medicine. 26: 570-2. PMID 21472500 DOI: 10.1007/S11606-011-1714-9 |
0.305 |
|
| 2010 |
Farley JF, Dusetzina SB. Medicaid prescription drug utilization and expenditures following Part D. Journal of Health Care For the Poor and Underserved. 21: 715-28. PMID 20453368 DOI: 10.1353/Hpu.0.0278 |
0.343 |
|
| 2010 |
Hansen RA, Dusetzina SB, Dominik RC, Gaynes BN. Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiology and Drug Safety. 19: 33-7. PMID 19998397 DOI: 10.1002/Pds.1881 |
0.506 |
|
| 2010 |
Dusetzina S, Hansen R, Farley J, Weinberger M, Sleath B, Gaynes B. PMH86 AGE RELATED TREATMENT DIFFERENCES AMONG CHILDREN WITH BIPOLAR SPECTRUM DISORDERS Value in Health. 13: A120-A121. DOI: 10.1016/S1098-3015(10)72581-X |
0.385 |
|
| 2009 |
Hansen RA, Dusetzina SB, Song L, Gaynes BN, Tu W, Murray MD. Depression affects adherence measurement but not the effectiveness of an adherence intervention in heart failure patients. Journal of the American Pharmacists Association : Japha. 49: 760-8. PMID 19926556 DOI: 10.1331/Japha.2009.08184 |
0.477 |
|
| 2009 |
Hansen RA, Moore CG, Dusetzina SB, Leinwand BI, Gartlehner G, Gaynes BN. Controlling for drug dose in systematic review and meta-analysis: a case study of the effect of antidepressant dose. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 29: 91-103. PMID 19141788 DOI: 10.1177/0272989X08323298 |
0.695 |
|
| Show low-probability matches. |